IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: The NCT01872442 trial assessed the safety and effectiveness of dasatinib with low dosage of peg-IFN-α2b as a first-line therapy for CML-CP patients, and a French NiloPeg study demonstrated the synergistic effects of peg-IFN-α2b and nilotinib [122,123].